The gene whose role in cancer development has till now baffled scientists around the world is commonly known as A20 or TNFAIP3.
It functions properly in healthy individuals. However, individuals develop cancer if for some reason the gene fails to function. Thus, many cancer patients are known to carry a dysfunctional variety of the gene.
The scientists came up with the first animal model of A20 to understand how this gene works in the body. Based on results over the past decade, they expected that these animals would develop cancer. But to their surprise, they found that the animals had a largely healthy life-span.
Chozha Rathinam, also of Indian origin, and Teruki Dainichi, currently at the Kyoto University, are the other authors of the report and who supported the research study.
The research work was highlighted by the peer-reviewed European Molecular Biology Organization (EMBO) Reports, which highlights only articles considered to be of "fundamental relevance to a general readership".
Professor Henning Walczak, Scientific Director of Cancer Research UK and Chairman of University College London, noted the importance the work.
"Before this work, there was no animal model to understand how this critical tumor suppress or works.
"Having an animal model now, significantly improves our ability to investigate how A20 works and this study already goes a long way in clarifying how A20 fails to work properly in patients and, as a consequence thereof, in developing potential cancer therapeutics," Prof Walczak said.
According to the latest figures by the World Health Organisation (WHO), 8.2 million people die from cancer every year. The WHO website states that more than 100 different types of cancer exists, each requiring unique diagnosis and treatment.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
